2023

	688238.SH

2023 20,480.50 29.69%

-12,793.83 425.90%

-13,354.89 476.11%

-9,012.18 520.65% 2023

CDMO

CGT CDMO

CGT CDMO

{2022}61

10,000.00 1.00 13.23

1,323,000,000.00

1,197,464,432.14 2022 3 22

2022 3 22 2025 12 31

2023 1 1 2023 12 31

2023

1	
2	
3	
4	
5	2024 4 20 2024 4 25

15	

16

[redacted]

15	

1

2

1

2

3

1

2

	269,094,176.43
	116,094,176.43

1	1		98860078801600001960	114,400,577.22
			98860078801100001959	270,084.98
2			121929394110858	-
			121938180510616	-
3	2		50131000890396571	1,423,514.23
4			2900001010120100061913	-
		-	-	**116,094,176.43**

		2015/12/8	2025/9/12	94,465,800	122,805,540	28,339,740		
		2020/10/10	2025/9/12	0	975,000	975,000		
		2019/12/16	2025/9/12					
		2015/12/8	2025/9/12	7,118,800	9,254,440	2,135,640		
		2015/12/8	2025/9/12	6,723,600	8,740,680	2,017,080		
		2022/5/18	2025/9/12	0	84,500	84,500		
		2020/10/10	2025/9/12	0	0	0		
		2022/9/13	2023/12/2	0	0	0		

GANGWANG		2020/12/29	2025/9/12	0	0	0		
		2020/12/29	2025/9/12	0	0	0		
		2020/12/29	2025/9/12	0	0	0		
		2021/4/2	2023/12/2	0	0	0		
		2020/3/20	2022/9/13	0	0	0		
		2022/9/13	2025/9/12					
		2022/9/13	2025/9/12	0	0	0		
		2020/11/9	2025/9/12	0	0	0		
		2016/12/16	2025/9/12	0	650,000	650,000		
		2016/12/16	2025/9/12	5,969,600	7,760,480	1,790,880		
		2020/12/14	2025/9/12	0	455,000	455,000		

（本页无正文，为《海通证券股份有限公司关于和元生物技术（上海）股份有限公司 2023 年度持续督导年度跟踪报告》之签字盖章页）

保荐代表人签名：

陈恒瑞　　张子慧

海通证券股份有限公司